000			02280na a2200289 4500
003			H12O
005			20180417112629.0
008			130622s2011 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aCastellano, Daniel _9882 _eOncología Médica
100			_aCortés-Funes Castro, Hernán _91181 _eOncología Médica
100			_aGarcía Escobar, Ignacio _91792 _eOncología Médica
100			_9433 _aSepúlveda Sánchez, Juan Manuel _eOncología Médica
100			_aRodríguez Antolín, Alfredo _91692 _eUrología
245	0	3	_aThe role of RANK-ligand inhibition in cancer: The story of denosumab _h[artículo]
260			_bOncologist, _c2011
300			_a16(2):136-145.
500			_aFormato Vancouver: Castellano D, Sepúlveda JM, García Escobar I, Rodriguez Antolín A, Sundlöv A, Cortés-Funes H. The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist. 2011;16(2):136-45.
501			_aPMID: 21285392
504			_aContiene 55 referencias
520			_aThe diagnosis of bone metastases is an event with certain consequences for the patient. They often mean pain and can also mean pathological fractures, hypercalcemia, and spinal cord compression, all synonymous with a diminished quality of life and often also hospitalization. Since the advent of the intravenous bisphosphonates, things began to look a bit brighter for patients with bone metastases-bone destruction was kept at bay a little longer. The next generation of bone metastasis treatments is well on its way in clinical development, and among them, the most advanced drug is denosumab. Denosumab is a fully human monoclonal antibody that inhibits osteoclast maturation, activation, and function by binding to receptor activator of nuclear factor kappa B ligand, with the final result being a reduced rate of bone resorption. In this review, we give an overview of relevant preclinical and clinical data regarding the use of denosumab in patients with solid tumors in general and prostate cancer in particular. The Oncologist 2011; 16: 136-145
710			_9303 _aServicio de Oncología Médica
710			_9220 _aServicio de Urología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/7/pc7820a.pdf _ySolicitar documento
942			_n0 _2ddc _cART
999			_c7820 _d7820